This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Jingwu Zang
Founder and Honorary Chairman at I-Mab Biopharma (NASDAQ: IMAB)

Profile

Dr. Zang founded I-Mab in 2016 and brought the Company to NASDAQ in early 2020. Under his leadership, I-Mab has evolved from an early-stage discovery company into a clinical stage company with an innovative and globally competitive pipeline in only four years. Prior to founding I-Mab, Dr. Zang held various senior executive positions in global and China pharma groups, including Senior Vice President and head of Neuroscience Therapeutic Area and head of China R&D Center with GlaxoSmithKline and Chief Scientific Officer and President with Simcere Pharmaceuticals and BioSciKin, an innovative drug development platform. Dr. Zang started his academic pursuit at Dr. L. Willems Institute in Belgium where he was head of multiple sclerosis research unit and later became Professor of Neurology and Immunology and Research Director of Multiple Sclerosis Center at Baylor College of Medicine in US. During his academic career in China, Dr. Zang founded the Institute of Health Sciences and co-founded the Institute Pasteur Shanghai with the Chinese Academy of Sciences. He also served as Dean of School of Medical Sciences at the Shanghai JiaoTong University and Director of Shanghai Institute of Immunology. Dr. Zang published more than 130 scientific articles and book chapters in prestigious journals and publications, including in Science, Nature Medicine, Nature Immunology, Immunity. Dr. Zang received his medical degree from Shanghai JiaoTong University School of Medicine, Ph.D. in Immunology from University of Brussels and completed his postdoctoral fellowship at Harvard Medical School. Dr. Zang is a licensed physician (Texas Medical Board) in US.

Agenda Sessions

  • Oncology: The in-rush of funds for IO and non-IO

    On Demand